THZ1 administration at both 5 and 10 mg/kg also significantly inhibited the growth of xenograft tumours originating from SW1990 cells with KRAS‐G12D mutation, but no significant discrepancy in the inhibitory effects was noted between the two dose groups (Figure 2C,D). Here, KRAS is linked to neoplasm.